- Home
- MSB vs ALEC Comparison
MSB vs ALEC Comparison
Compare MSB & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSB | ALEC |
|---|---|---|
| Founded | 1961 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.2M | 275.8M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MSB | ALEC |
|---|---|---|
| Price | $18.79 | $1.82 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.90 |
| AVG Volume (30 Days) | 49.1K | ★ 4.0M |
| Earning Date | 04-24-2026 | 11-05-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $98,595,651.00 | $21,045,000.00 |
| Revenue This Year | N/A | $214.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $254.37 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.25 | $1.09 |
| 52 Week High | $42.38 | $2.76 |
Technical Indicators
Market Signals| Indicator | MSB | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 44.29 |
| Support Level | $18.50 | $1.43 |
| Resistance Level | $24.64 | $2.17 |
| Average True Range (ATR) | 0.87 | 0.20 |
| MACD | 0.22 | -0.00 |
| Stochastic Oscillator | 51.57 | 22.55 |
Price Performance
Historical ComparisonAbout MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the northeastern end of the Mesabi Iron Range.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.